CMMB Q3 2024 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$3M

EPS (Diluted)

$-0.80

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$21M

Total Liabilities

$5M

Stockholders' Equity

$16M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$18,938	+100.0%
Operating Income	-$4M	-$4M	+15.0%
Net Income	-$3M	-$4M	+14.4%